Search

The increasing knowledge of the influence of the immune system on tumour development and progression has fundamentally changed our understanding of tumour biology in recent years. While the available treatment options for patients with metastatic urothelial carcinoma of the urinary bladder have hardly improved over decades, the advent of immune checkpoint inhibitors has caused major changes in the corresponding treatment landscape.Although cisplatin-based combination therapies remain the main element, additional effective treatment options now exist with the PD-(L)-1 inhibitors atezolizumab, pembrolizumab and nivolumab, which have been approved in Europe. A remarkable long-term response is balanced by the occurrence of occasionally severe immune-mediated side effects and an overall low response rate of approximately 25 %. A large number of current clinical trials therefore address possible combinatory approaches in order to make optimal use of possible synergisms and additive effects of the substances available to date, taking into account an acceptable side effect profile. In addition, many new therapeutic approaches are also being tested in clinical trials. In this context, developments in the field of antibody-drug conjugates and FGFR inhibitors with regards to the very recent FDA approvals are particularly noteworthy.The present review provides an overview of currently available treatment options in metastatic urothelial carcinoma of the bladder and especially focuses on future therapeutic approaches based on current clinical trials., Competing Interests: GN: Vortragstätigkeiten: Pfizer Pharma GmbH (seit 2016), Roche Pharma AG (seit 2016), medac GmbH (seit 2017) Advisory Boards, Beratertätigkeit: Roche Parma AG (seit 2015), IMS Health AG (2016-2018), BMS AG (2016), Sanofi-Aventis (2018) Reisekosten- und Fortbildungsunterstützung: Roche Parma AG (seit 2015), medac GmbH (seit 2017), Pfizer Pharma GmbH (seit 2016), (© Georg Thieme Verlag KG Stuttgart · New York.)